Idorsia Pharmaceutical has been granted a patent for a synthetic oligosaccharide related to Klebsiella pneumoniae serotypes O3, O3b, and/or O5. The oligosaccharide can be used in the prevention and treatment of diseases associated with the bacteria, as well as in immunological assays for antibody detection. GlobalData’s report on Idorsia Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Idorsia Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Idorsia Pharmaceutical's grant share as of February 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for synthetic oligosaccharide for klebsiella pneumoniae treatment
A recently granted patent (Publication Number: US11891413B2) discloses an oligosaccharide compound of general formula (II) that can be used in pharmaceutical compositions and conjugates for raising a protective immune response in human and animal hosts. The oligosaccharide compound, represented by the formula T*-[(—Ux+4—Ux+3—Ux+2—Ux+1—Ux)m—(Vx+2—Vx+1—Vx)1-m]n—O-L-E, has various applications in treating diseases associated with Klebsiella pneumonia serotype O3, O3b, and/or O5 bacteria, such as pneumonia, bronchitis, meningitis, urinary tract infection, and more. The patent also covers methods for administering the conjugates to elicit an immune response and treat the mentioned diseases.
Furthermore, the patent includes claims for pharmaceutical compositions containing the oligosaccharide compound and conjugates, along with pharmaceutically acceptable adjuvants and excipients. The conjugates consist of the oligosaccharide compound covalently linked to an immunogenic carrier, such as carrier proteins like diphtheria toxoid, tetanus toxoid, or non-lipidated cell-surface lipoprotein of non-typeable Haemophilus influenzae. These compositions and conjugates aim to provide effective treatment options for diseases caused by Klebsiella pneumonia bacteria, offering a potential solution for conditions like wound infections, septicemia, and ankylosing spondylitis. The patent's comprehensive coverage of the oligosaccharide compound and its conjugates underscores their potential in immunotherapy and disease management, particularly in the context of bacterial infections associated with Klebsiella pneumonia serotypes.
To know more about GlobalData’s detailed insights on Idorsia Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
